Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BG-71332 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| BG-71332, Zanubrutinib + Sonrotoclax | EXPERIMENTAL | Participants will receive the following treatments in one of six sequences: one dose of BG-71332 with a high-fat meal, one dose of BG-71332 in a fasted state, and one dose of zanubrutinib and sonrotoclax administered together with a high-fat meal. |
| Name | Type | Description |
|---|---|---|
| BG-71332 | DRUG | Administered orally |
| Zanubrutinib | DRUG | Administered orally |
| Sonrotoclax | DRUG | Administered orally |
Inclusion Criteria: * In good health, determined by no clinically significant findings from medical history, 12-lead ECGs, vital sign measurements, and clinical laboratory evaluations as assessed by the investigator. * An absolute B-cell count of \>200 cells/μL. * Female participants must be of non...
BG-71332 is an investigational small molecule developed by BeOne Medicines Ltd. It is a fixed-dose combination tablet containing zanubrutinib and sonrotoclax. It has been studied in a Phase 1 clinical trial in healthy adult volunteers, and no therapeutic indication has been disclosed for the asset.
BG-71332 is being developed by BeOne Medicines Ltd., which trades under the ticker ONC. The company sponsored the Phase 1 trial of the fixed-dose combination tablet containing zanubrutinib and sonrotoclax that was conducted in healthy adult volunteers in Australia.
BG-71332 is in Phase 1 development. One Phase 1 trial has been completed, and no active trials are currently listed. The completed study enrolled 24 healthy adult volunteers and evaluated the relative bioavailability and food effect of the fixed-dose combination tablet.
BG-71332 has been evaluated in one clinical trial, NCT07141511, titled a study to investigate the relative bioavailability and food effect of a fixed-dose combination tablet containing zanubrutinib and sonrotoclax (BG-71332) in healthy adults. The Phase 1 trial enrolled 24 participants in Australia and is completed.
The completed Phase 1 trial NCT07141511 measured the relative bioavailability and food effect of the fixed-dose combination tablet containing zanubrutinib and sonrotoclax in healthy adult volunteers. It was an uncontrolled study with 24 enrolled participants, conducted in Australia, and it included randomization.
BG-71332 is a fixed-dose combination tablet containing both zanubrutinib and sonrotoclax, so it is not the same as either agent alone. It combines the two components into a single tablet, and it was studied in healthy adult volunteers in a Phase 1 trial.